A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI
Year: 2011
Type: article
Abstract: CONTEXT: There is no rapid and cost effective tool that can be implemented as a front-line screening tool for Alzheimer's disease (AD) at the population level. OBJECTIVE: To generate and cross-validate a blood-based screener for AD that yields acceptable accuracy across both serum and plasma. DESIGN, SETTING, PARTICIPANTS: Analysis of serum biomarker proteins were conducted on 197 Alzheimer's disease (AD) participants and 199 control participants from the Texas Alzheimer's Research Consortium (TARC) with further analysis conducted on plasma proteins from 112 AD and 52 control participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The full algorithm was derived from a biomarker risk score, clinical lab (glucose, triglycerides, total cholesterol, homocysteine), and demographic (age, gender, education, APOE*E4 status) data. MAJOR OUTCOME MEASURES: Alzheimer's disease. RESULTS: 11 proteins met our criteria and were utilized for the biomarker risk score. The random forest (RF) biomarker risk score from the TARC serum samples (training set) yielded adequate accuracy in the ADNI plasma sample (training set) (AUC = 0.70, sensitivity (SN) = 0.54 and specificity (SP) = 0.78), which was below that obtained from ADNI cerebral spinal fluid (CSF) analyses (t-tau/Aβ ratio AUC = 0.92). However, the full algorithm yielded excellent accuracy (AUC = 0.88, SN = 0.75, and SP = 0.91). The likelihood ratio of having AD based on a positive test finding (LR+) = 7.03 (SE = 1.17; 95% CI = 4.49-14.47), the likelihood ratio of not having AD based on the algorithm (LR-) = 3.55 (SE = 1.15; 2.22-5.71), and the odds ratio of AD were calculated in the ADNI cohort (OR) = 28.70 (1.55; 95% CI = 11.86-69.47). CONCLUSIONS: It is possible to create a blood-based screening algorithm that works across both serum and plasma that provides a comparable screening accuracy to that obtained from CSF analyses.
Source: PLoS ONE
Institutions: Texas Tech University, Texas Tech University Health Sciences Center, The University of Texas Southwestern Medical Center, University of North Texas, University of North Texas Health Science Center, University of North Carolina at Chapel Hill, Mayo Clinic, Mayo Clinic in Florida, Baylor College of Medicine, Uniformed Services University of the Health Sciences, Center for Neuroscience and Regenerative Medicine
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Foundation for the National Institutes of Health, Alzheimer's Association, CH Foundation, Dana Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Novartis, F. Hoffmann-La Roche, Medpace, Texas Tech University, Synarc, Alzheimer's Disease Neuroimaging Initiative, University of Texas Southwestern Medical Center, Cynthia and George Mitchell Foundation, University of North Texas, Northern California Institute for Research and Education, Elan, Eisai, National Institutes of Health, U.S. Food and Drug Administration, Genentech, University of California, Los Angeles, University of California, San Diego, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
Awards: G104586243, G1103752518, UC Davis Alzheimer's Disease Core Center, G2152643862, G2283900753, G2409989180, Neurobiology of Alzheimer's Disease and Aging, G2835601961, G2844381683, G2877684854, G29951154, G3131374986, G3146424788, G3218891203, G3553156159, G3705772492, G3710456697, G378970345, G3870774570, G3966393351, "MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies", G43180419, G4401988282, G4660785924, G4684857399, G5207404921, G5209990037, G5366509656, G5389965057, Alzheimer's Disease Neuroimaging Initiative, G598830915, G6069485058, G6259281481, G6412110892, G6899163935, G6948409098, G7315666996, G7414321945, G7799614282, G781725486, Alzheimer's Disease Cooperative Study, G793122433, G8636843673, G9000039018, G9000074849, G9000108235, G9000122335, G920654007, G991187644
OpenAlex ID: W2097452416